 |
|
|
| |
Long-term Treatment Efficacy and
Safety Following Switch to Doravirine/
Lamivudine/Tenofovir Disoproxil Fumarate
(DOR/3TC/TDF): Week 144 Results of the
DRIVE-SHIFT Trial
|
| |
| |
Glasgow 2020 Oct 5-8 virtual
Reported by Jules Levin
Princy Kumar1; Margaret Johnson2; Jean-Michel Molina3; Giuliano Rizzardini4; Pedro Cahn5; Markus Bickel6; Hong Wan7; Cristiana Morais7; Peter Sklar7; Wayne Greaves7 for the DRIVE-SHIFT Study Group
1Georgetown University, Washington DC, USA; 2Royal Free Hospital, London, UK; 3University of Paris Diderot and Hopital Saint-Louis, Paris, France; 4Fatebenefratelli Sacco Hospital, Milan, Italy; 5Fundacion Huesped, Buenos Aires, Argentina; 6Infektiologikum, Frankfurt, Germany; 7Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
